gabapentin has been researched along with Chronic Insomnia in 24 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We will include all randomised controlled trials (RCTs) reported as double-blind and comparing gabapentin or pregabalin with placebo or any other active pharmacological treatment (any preparation, dose, frequency, route of delivery or setting) in patients with bipolar disorder, anxiety or insomnia." | 8.95 | Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a systematic review and meta-analysis. ( Atkinson, LZ; Awad, A; Cipriani, A; Forrest, A; Geddes, JR; Harrison, PJ; Houghton, KT; Stockton, S, 2017) |
| "We will include all randomised controlled trials (RCTs) reported as double-blind and comparing gabapentin or pregabalin with placebo or any other active pharmacological treatment (any preparation, dose, frequency, route of delivery or setting) in patients with bipolar disorder, anxiety or insomnia." | 4.95 | Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a systematic review and meta-analysis. ( Atkinson, LZ; Awad, A; Cipriani, A; Forrest, A; Geddes, JR; Harrison, PJ; Houghton, KT; Stockton, S, 2017) |
| "We present a totally blind adolescent with refractory insomnia due to a combination of Non-24 hour sleep-wake disorder and restless leg syndrome that was successfully treated with tasimelteon, iron replacement, and gabapentin." | 3.91 | Refractory Insomnia in an Adolescent with Total Blindness. ( Combs, D; Grandner, MA; Tubbs, AS, 2019) |
| " The outcome measures included scores: (1) for the improvement in the degree of sleep interference score; (2) for the improvement in sleep quality; (3) for the rate of poor sleep quality; (4) for the rate awakenings of >5 per night; and (5) for the incidence of adverse reactions." | 3.01 | Efficacy and Safety of Gabapentin in Improving Sleep Quality of Patients with Sensory Nervous System Diseases: A Meta-Analysis. ( Jiang, W; Li, W; Ma, M; Shen, Y, 2023) |
| "Gabapentin was associated with significantly higher values of KSD Sleep Quality Index and reported TST versus placebo; no other reported outcomes were significant." | 2.79 | A randomized, double-blind, single-dose, placebo-controlled, multicenter, polysomnographic study of gabapentin in transient insomnia induced by sleep phase advance. ( Furey, SA; Hull, SG; Jayawardena, S; Lankford, DA; Mayleben, DW; Rosenberg, RP; Roth, T; Seiden, DJ, 2014) |
| "Gabapentin was associated with less %stage1 on Day 1, and greater %REM on Day 28, versus placebo." | 2.79 | A randomized, double-blind, placebo-controlled, multicenter, 28-day, polysomnographic study of gabapentin in transient insomnia induced by sleep phase advance. ( Furey, SA; Hull, SG; Jayawardena, S; Leibowitz, MT; Roth, T, 2014) |
| " Using plasma gabapentin concentration data obtained after administration of GEn in 12 phase 1 to 3 GEn studies in healthy adults or patients with RLS (dose range, 300-2400 mg/d), a population pharmacokinetic (PK) model was developed by nonlinear mixed-effect modeling using NONMEM." | 2.78 | Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil. ( Cundy, KC; Lal, R; Lassauzet, ML; Luo, W; Sukbuntherng, J; Tovera, J, 2013) |
| "Gabapentin is a calcium channel GABAergic modulator that is widely used for pain." | 2.58 | Gabapentin for the treatment of alcohol use disorder. ( Mason, BJ; Quello, S; Shadan, F, 2018) |
| "Chronic orofacial pain can greatly improve following treatment of the underlying insomnia, and therefore, re-evaluation of COFP is advised after 1 month of treatment." | 2.55 | An update of management of insomnia in patients with chronic orofacial pain. ( Almoznino, G; Benoliel, R; Haviv, Y; Sharav, Y, 2017) |
| "The consequences of insomnia, including issues with mood, behavior, and cognition, are discussed." | 2.53 | Pediatric Insomnia. ( Brown, KM; Malow, BA, 2016) |
| "Insomnia in patients with alcohol dependence has increasingly become a target of treatment due to its prevalence, persistence, and associations with relapse and suicidal thoughts, as well as randomized controlled studies demonstrating efficacy with behavior therapies and non-addictive medications." | 2.52 | Assessment and treatment of insomnia in adult patients with alcohol use disorders. ( Brower, KJ, 2015) |
| "This review aims to analyze pharmacokinetic profile, plasma level variations so as the metabolism, interactions and possible relation to clinical effect of several drugs which are used primarily as anxiolytics." | 2.49 | Understanding the pharmacokinetics of anxiolytic drugs. ( Altamura, AC; Bareggi, S; Maffini, M; Mauri, MC; Moliterno, D; Paletta, S, 2013) |
| "Cases with EoE with a psychiatric diagnosis were more likely to be women, white, and 18 years or older and to have a longer symptom duration before diagnosis." | 1.56 | Psychiatric Comorbidities and Psychiatric Medication Use Are Highly Prevalent in Patients With Eosinophilic Esophagitis and Associate With Clinical Presentation. ( Corder, SR; Dellon, ES; Eluri, S; Kim, E; Reed, CC; Sanders, E; Tappata, M, 2020) |
| "Chronic neuropathic pain following traumatic brachial plexus injury could be successfully managed by chemical neurolysis and oral gabapentin." | 1.51 | Management of neuropathic pain following traumatic brachial plexus injury with neurolysis and oral gabapentin: A case report. ( Aaron, OI; Adetoye, AO; Orimolade, EA; P Adetifa, KA, 2019) |
| "Gabapentin has shown promise in treating insomnia in adults." | 1.39 | Gabapentin shows promise in treating refractory insomnia in children. ( Malow, BA; Robinson, AA, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (20.83) | 29.6817 |
| 2010's | 15 (62.50) | 24.3611 |
| 2020's | 4 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Hong, JSW | 1 |
| Atkinson, LZ | 2 |
| Al-Juffali, N | 1 |
| Awad, A | 2 |
| Geddes, JR | 2 |
| Tunbridge, EM | 1 |
| Harrison, PJ | 2 |
| Cipriani, A | 2 |
| Saul, H | 3 |
| Gursul, D | 3 |
| Cassidy, S | 3 |
| Harrison, P | 3 |
| Shen, Y | 1 |
| Li, W | 1 |
| Ma, M | 1 |
| Jiang, W | 1 |
| Adetoye, AO | 1 |
| Aaron, OI | 1 |
| Orimolade, EA | 1 |
| P Adetifa, KA | 1 |
| Reed, CC | 1 |
| Corder, SR | 1 |
| Kim, E | 1 |
| Sanders, E | 1 |
| Tappata, M | 1 |
| Eluri, S | 1 |
| Dellon, ES | 1 |
| Houghton, KT | 1 |
| Forrest, A | 1 |
| Stockton, S | 1 |
| Mason, BJ | 1 |
| Quello, S | 1 |
| Shadan, F | 1 |
| Tubbs, AS | 1 |
| Grandner, MA | 1 |
| Combs, D | 1 |
| DelRosso, LM | 1 |
| Jackson, CV | 1 |
| Ferri, R | 1 |
| Rosenberg, RP | 1 |
| Hull, SG | 2 |
| Lankford, DA | 1 |
| Mayleben, DW | 1 |
| Seiden, DJ | 1 |
| Furey, SA | 2 |
| Jayawardena, S | 2 |
| Roth, T | 2 |
| Leibowitz, MT | 1 |
| Brower, KJ | 4 |
| Brown, KM | 1 |
| Malow, BA | 2 |
| Almoznino, G | 1 |
| Haviv, Y | 1 |
| Sharav, Y | 1 |
| Benoliel, R | 1 |
| Myra Kim, H | 1 |
| Strobbe, S | 1 |
| Karam-Hage, MA | 1 |
| Consens, F | 1 |
| Zucker, RA | 1 |
| Kushida, CA | 1 |
| Becker, PM | 1 |
| Ellenbogen, AL | 1 |
| Canafax, DM | 1 |
| Barrett, RW | 1 |
| Konno, M | 1 |
| Uchiyama, M | 1 |
| Lucey, BP | 1 |
| Noetzel, MJ | 1 |
| Duntley, SP | 1 |
| Guttuso, T | 1 |
| Robinson, AA | 1 |
| Altamura, AC | 1 |
| Moliterno, D | 1 |
| Paletta, S | 1 |
| Maffini, M | 1 |
| Mauri, MC | 1 |
| Bareggi, S | 1 |
| Lal, R | 1 |
| Sukbuntherng, J | 1 |
| Luo, W | 1 |
| Tovera, J | 1 |
| Lassauzet, ML | 1 |
| Cundy, KC | 1 |
| Karam-Hage, M | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Single-Dose, Placebo-Controlled, Multicenter, Polysomnographic Study Of Gabapentin 250 mg And 500 mg In Transient Insomnia Induced By A Sleep Phase Advance[NCT00674752] | Phase 3 | 377 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| Impact of Gabapentin on Slow Wave Sleep in Adult Critically Ill Patient.[NCT04818450] | 60 participants (Actual) | Interventional | 2021-04-19 | Completed | |||
| A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 28-day, Polysomnographic Study of Gabapentin 250 mg in Transient Insomnia Induced by a Sleep Phase Advance[NCT00163046] | Phase 3 | 256 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for gabapentin and Chronic Insomnia
| Article | Year |
|---|---|
Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: Systematic review, meta-analysis, and rationale.
Topics: Amines; Anxiety; Bipolar Disorder; Calcium Channels; Cyclohexanecarboxylic Acids; Gabapentin; gamma- | 2022 |
Little evidence supports gabapentinoid use in bipolar disorder or insomnia.
Topics: Bipolar Disorder; Gabapentin; Humans; Pregabalin; Sleep Initiation and Maintenance Disorders | 2022 |
Little evidence supports gabapentinoid use in bipolar disorder or insomnia.
Topics: Bipolar Disorder; Gabapentin; Humans; Pregabalin; Sleep Initiation and Maintenance Disorders | 2022 |
Little evidence supports gabapentinoid use in bipolar disorder or insomnia.
Topics: Bipolar Disorder; Gabapentin; Humans; Pregabalin; Sleep Initiation and Maintenance Disorders | 2022 |
Little evidence supports gabapentinoid use in bipolar disorder or insomnia.
Topics: Bipolar Disorder; Gabapentin; Humans; Pregabalin; Sleep Initiation and Maintenance Disorders | 2022 |
Little evidence supports gabapentinoid use in bipolar disorder or insomnia.
Topics: Bipolar Disorder; Gabapentin; Humans; Pregabalin; Sleep Initiation and Maintenance Disorders | 2022 |
Little evidence supports gabapentinoid use in bipolar disorder or insomnia.
Topics: Bipolar Disorder; Gabapentin; Humans; Pregabalin; Sleep Initiation and Maintenance Disorders | 2022 |
Little evidence supports gabapentinoid use in bipolar disorder or insomnia.
Topics: Bipolar Disorder; Gabapentin; Humans; Pregabalin; Sleep Initiation and Maintenance Disorders | 2022 |
Little evidence supports gabapentinoid use in bipolar disorder or insomnia.
Topics: Bipolar Disorder; Gabapentin; Humans; Pregabalin; Sleep Initiation and Maintenance Disorders | 2022 |
Little evidence supports gabapentinoid use in bipolar disorder or insomnia.
Topics: Bipolar Disorder; Gabapentin; Humans; Pregabalin; Sleep Initiation and Maintenance Disorders | 2022 |
Efficacy and Safety of Gabapentin in Improving Sleep Quality of Patients with Sensory Nervous System Diseases: A Meta-Analysis.
Topics: Chronic Disease; Gabapentin; Humans; Multicenter Studies as Topic; Sleep; Sleep Initiation and Maint | 2023 |
Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a systematic review and meta-analysis.
Topics: Amines; Anti-Anxiety Agents; Anxiety Disorders; Bipolar Disorder; Cyclohexanecarboxylic Acids; Doubl | 2017 |
Gabapentin for the treatment of alcohol use disorder.
Topics: Alcohol Drinking; Alcoholism; Amines; Animals; Calcium Channel Blockers; Cyclohexanecarboxylic Acids | 2018 |
Assessment and treatment of insomnia in adult patients with alcohol use disorders.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Amines; Anti-Anxiety Agents; Anticonvulsants; Antipsych | 2015 |
Pediatric Insomnia.
Topics: Actigraphy; Adolescent; Amines; Anti-Anxiety Agents; Autism Spectrum Disorder; Central Nervous Syste | 2016 |
An update of management of insomnia in patients with chronic orofacial pain.
Topics: Amines; Anticonvulsants; Antidepressive Agents; Benzodiazepines; Chronic Pain; Cognitive Behavioral | 2017 |
[Update on the treatment of restless legs syndrome].
Topics: Amines; Analgesics, Opioid; Anticonvulsants; Baths; Benzodiazepines; Cyclohexanecarboxylic Acids; Do | 2009 |
Understanding the pharmacokinetics of anxiolytic drugs.
Topics: Adrenergic beta-Antagonists; Amines; Anti-Anxiety Agents; Anticonvulsants; Anxiety Disorders; Atenol | 2013 |
7 trials available for gabapentin and Chronic Insomnia
| Article | Year |
|---|---|
A randomized, double-blind, single-dose, placebo-controlled, multicenter, polysomnographic study of gabapentin in transient insomnia induced by sleep phase advance.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Calcium Channel Blockers; Cyclohexanecarboxylic | 2014 |
A randomized, double-blind, single-dose, placebo-controlled, multicenter, polysomnographic study of gabapentin in transient insomnia induced by sleep phase advance.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Calcium Channel Blockers; Cyclohexanecarboxylic | 2014 |
A randomized, double-blind, single-dose, placebo-controlled, multicenter, polysomnographic study of gabapentin in transient insomnia induced by sleep phase advance.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Calcium Channel Blockers; Cyclohexanecarboxylic | 2014 |
A randomized, double-blind, single-dose, placebo-controlled, multicenter, polysomnographic study of gabapentin in transient insomnia induced by sleep phase advance.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Calcium Channel Blockers; Cyclohexanecarboxylic | 2014 |
A randomized, double-blind, placebo-controlled, multicenter, 28-day, polysomnographic study of gabapentin in transient insomnia induced by sleep phase advance.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Calcium Channel Blockers; Cyclohexanecarboxylic | 2014 |
A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia.
Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Antimanic Agents; Cyclohexanecarboxylic Acids; Dose-Res | 2008 |
Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS.
Topics: Adult; Amines; Anti-Anxiety Agents; Carbamates; Central Nervous System; Cyclohexanecarboxylic Acids; | 2009 |
Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Carbamates; Cyclohexanecarboxylic Acids; Female; | 2013 |
Open pilot study of gabapentin versus trazodone to treat insomnia in alcoholic outpatients.
Topics: Acetates; Alcoholism; Amines; Antidepressive Agents, Second-Generation; Cyclohexanecarboxylic Acids; | 2003 |
Gabapentin treatment for insomnia associated with alcohol dependence.
Topics: Acetates; Adult; Alcoholism; Amines; Anticonvulsants; Comorbidity; Cyclohexanecarboxylic Acids; Fema | 2000 |
7 other studies available for gabapentin and Chronic Insomnia
| Article | Year |
|---|---|
Management of neuropathic pain following traumatic brachial plexus injury with neurolysis and oral gabapentin: A case report.
Topics: Adult; Aged; Analgesics; Brachial Plexus; Brachial Plexus Neuropathies; Bupivacaine; Gabapentin; Hum | 2019 |
Psychiatric Comorbidities and Psychiatric Medication Use Are Highly Prevalent in Patients With Eosinophilic Esophagitis and Associate With Clinical Presentation.
Topics: Adolescent; Adult; Age Distribution; Anxiety Disorders; Benzodiazepines; Chest Pain; Child; Chronic | 2020 |
Refractory Insomnia in an Adolescent with Total Blindness.
Topics: Adolescent; Benzofurans; Blindness; Cyclopropanes; Drug Resistance; Drug Therapy, Combination; Femal | 2019 |
A 15-Year-Old Girl With Sleep-Onset Insomnia and Poor Sleep Quality.
Topics: Adolescent; Anticonvulsants; Diagnosis, Differential; Female; Gabapentin; Humans; Restless Legs Synd | 2019 |
Paroxysmal arousals and myoclonic movements associated with interictal epileptiform discharges in NREM and REM sleep.
Topics: Adolescent; Amines; Antiparkinson Agents; Arousal; Chromosome Disorders; Chromosome Inversion; Chrom | 2011 |
Nighttime awakenings responding to gabapentin therapy in late premenopausal women: a case series.
Topics: Adult; Amines; Anti-Anxiety Agents; Cyclohexanecarboxylic Acids; Estradiol; Female; Follicle Stimula | 2012 |
Gabapentin shows promise in treating refractory insomnia in children.
Topics: Adolescent; Amines; Anticonvulsants; Child; Child, Preschool; Cyclohexanecarboxylic Acids; Female; F | 2013 |